quizartinib

Quizartinib is a small molecule receptor tyrosine kinase inhibitor used for the treatment of acute myeloid leukemia (AML) with FLT3 internal tandem duplication (ITD)-positive mutations. It acts by selectively inhibiting class III receptor tyrosine kinases, primarily fms-like tyrosine kinase 3 (FLT3), which is frequently mutated in AML and associated with poor prognosis. Quizartinib binds to the ATP-binding domain of FLT3, inhibiting its autophosphorylation and downstream signaling, thereby blocking leukemic cell proliferation dependent on FLT3-ITD. The drug is administered orally and can be used in combination with cytarabine and anthracycline induction/consolidation therapy or as maintenance monotherapy following consolidation chemotherapy. Quizartinib was developed specifically to target FLT3 mutations in AML and has demonstrated efficacy particularly in relapsed or refractory cases. It carries a risk of QT interval prolongation as a notable adverse effect[1][3][5].

Brand names

Vanflyta

Other names

Quizartinibum